Tag - remdesivir

 
 

REMDESIVIR

Japan Times
WORLD / Science & Health
Nov 20, 2020
WHO advises doctors not to use Gilead’s remdesivir for COVID-19
The recommendation is a blow to Gilead's drug, which was one of the first thought to offer a meaningful benefit in treatment of coronavirus patients.
Japan Times
WORLD / Science & Health
Oct 17, 2020
WHO says remdesivir and three other drugs have no effect on COVID-19 patients
The World Health Organization has said that trial results show remdesivir and three other drugs administered to people infected with the novel coronavirus "have little or no effect" in terms of lowering the morality rate.
Japan Times
JAPAN / Science & Health
Jul 22, 2020
Japan approves dexamethasone as second drug for coronavirus treatment
The inexpensive and easy-to-obtain drug is used to treat a wide range of conditions including lung disease.
Japan Times
BUSINESS / Companies
Jun 23, 2020
Gilead targets remdesivir supply for 2 million COVID-19 patients by year-end
The company also said it hoped to start trials in August of an easier-to-use inhaled version of the medicine, which is currently administered only intravenously.
Japan Times
WORLD / Science & Health
May 23, 2020
Gilead’s remdesivir mainly helped healthier COVID-19 patients
Gilead Sciences Inc.’s remdesivir, the first medicine cleared for the treatment of COVID-19, mainly benefited healthier patients who weren’t dependent on ventilators or heart-lung bypass machines, according to published results of the study used to get the medicine on the market.
Japan Times
ASIA PACIFIC / Science & Health
May 13, 2020
A tale of two Japanese drugs in tests to fight COVID-19
Avigan and camostat are undergoing trials as they may be effective in treating illnesses brought on by coronavirus.
Japan Times
JAPAN / FOCUS
May 12, 2020
Abe follows Trump's example, approving drugs quickly after criticism
Japanese regulators are usually known for taking a year to approve new drugs, but authorized remdesivir just three days after receiving the application.
Japan Times
WORLD / Science & Health
May 2, 2020
U.S. emergency approval broadens use of Gilead's COVID-19 drug remdesivir
Gilead Science Inc.'s antiviral drug remdesivir was granted emergency use authorization by the U.S. Food and Drug Administration for COVID-19 on Friday, clearing the way for broader use of the drug in more hospitals around the United States.
Japan Times
WORLD / Science & Health
May 1, 2020
Virus drugmaker caught between making a profit and treating the world
Gilead Sciences Inc. may spend $1 billion on its breakthrough new treatment for COVID-19 this year alone, Chief Executive Officer Daniel O’Day said. How much revenue — if any — the company expects to generate is another matter.
Japan Times
JAPAN / Science & Health
Apr 28, 2020
Remdesivir drug to be approved for coronavirus patients in May
This is the first time the government has used the streamlined process since the pandemic started.
Japan Times
WORLD / Science & Health
Apr 11, 2020
Two-thirds of severe COVID-19 cases improved with remdesivir drug
Gilead Sciences Inc.’s experimental drug for patients with severe COVID-19 infections showed promise in an early analysis, raising tentative hope that the first treatment for the novel virus may be on the horizon.
Japan Times
WORLD / Science & Health / FOCUS
Apr 6, 2020
Fast-moving virus pits treating patients against finding a cure
Pharmaceutical research experts are raising concerns that attempts to offer desperate coronavirus patients some form of treatment may hobble crucial studies of which drugs actually work and which ones don't.
JAPAN / Science & Health
Mar 24, 2020
Japan to join trial to test Ebola drug on COVID-19 patients
The National Center for Global Health and Medicine (NCGM) said Monday that it will join an international clinical trial on the use of remdesivir, which is being developed as a remedy for Ebola, to treat people infected with the new coronavirus.
BUSINESS
Feb 26, 2020
U.S. begins first coronavirus clinical trial testing Gilead's experimental drug
U.S. health officials said on Tuesday the first clinical trial testing Gilead Sciences Inc.'s experimental antiviral drug, remdesivir, in hospitalized patients with the coronavirus has started.
Japan Times
ASIA PACIFIC / Science & Health
Feb 14, 2020
Gilead drug prevents type of coronavirus in monkeys, raising hope for China trials
An experimental Gilead Sciences antiviral drug prevented disease and reduced the severity of symptoms in monkeys infected with Middle East respiratory syndrome (MERS), an infection closely related to the fast-spreading coronavirus that originated in China, a study published on Thursday found.
Japan Times
MULTIMEDIA
Feb 24, 2015
Ebola drug developed in Japan 'halved mortality rates' in some Guinea patients
A relatively cheap drug from a subsidiary of Fujifilm being tested against Ebola in Guinea has halved mortality rates in some patients.

Longform

High-end tourism is becoming more about the kinds of experiences that Japan's lesser-known places can provide.
Can Japan lure the jet-set class off the beaten path?